Abstract Number: 1008 • 2018 ACR/ARHP Annual Meeting
Presence of a Specific Defect in M2 Polarization of Blood Monocytes from Patients with Rheumatoid Arthritis, Associated with Increased microRNA-155
Background/Purpose: Macrophages contribute in situ to the RA pathogenesis. Two distinct states of polarization for macrophages have been recognized: the classically activated macrophage phenotype (M1),…Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting
Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients
Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…Abstract Number: 2331 • 2018 ACR/ARHP Annual Meeting
Obesity Might Positively Affect TNF Mediated Bone Metabolism in RA Patients
Background/Purpose: In this study, we tried to find out the effect of obesity on bone metabolism after one year of anti-TNF agent use. Methods: Thirty-two…Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting
Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD). While…Abstract Number: 2711 • 2017 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis
Background/Purpose: CD8+ T cells have been described to comprise up to 40% of the rheumatoid arthritis (RA) synovial T cell compartment but their pathogenic function…Abstract Number: 139 • 2017 ACR/ARHP Annual Meeting
No Effect of Tumor Necrosis Factor-a Inhibitors on Renal Function in Patients with Rheumatoid Arthritis from Kobio Registry from 2012 to 2016
Background/Purpose: Renal disease is prevalent in patients with rheumatoid arthritis (RA), although the precise prevalence of RA has not been determined. Increased mortality in patients…Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
- Background/Purpose: Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…
- 1
- 2
- 3
- …
- 6
- Next Page »